Terms: = Bone cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
59 results:
1. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract] [Full Text] [Related]
2. MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.
Wang Y; Chen J; Gong L; Wang Y; Siltari A; Lou YR; Murtola TJ; Gao S; Gao Y
J Nanobiotechnology; 2024 Apr; 22(1):145. PubMed ID: 38566211
[TBL] [Abstract] [Full Text] [Related]
3. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.
Song Y; Jin Z; Li ZM; Liu Y; Li L; He C; Su H; Zhou H; Li K; Hao S; Zuo X; Wu J; Li D; Wu M; Sun X; Qi J; Cai Z; Li Z; Li Y; Huang Y; Shen J; Xiao Z; Zhu J
Clin Cancer Res; 2024 Apr; 30(7):1248-1255. PubMed ID: 38190117
[TBL] [Abstract] [Full Text] [Related]
4. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
5. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of ezh2 mutations in follicular lymphoma.
Nagy Á; Bátai B; Kiss L; Gróf S; Király PA; Jóna Á; Demeter J; Sánta H; Bátai Á; Pettendi P; Szendrei T; Plander M; Körösmezey G; Alizadeh H; Kajtár B; Méhes G; Krenács L; Timár B; Csomor J; Tóth E; Schneider T; Mikala G; Matolcsy A; Alpár D; Masszi A; Bödör C
J Intern Med; 2023 Sep; 294(3):295-313. PubMed ID: 37259686
[TBL] [Abstract] [Full Text] [Related]
6. Capsaicin Reduces cancer Stemness and Inhibits Metastasis by Downregulating
Chen ZY; Huang HH; Li QC; Zhan FB; Wang LB; He T; Yang CH; Wang Y; Zhang Y; Quan ZX
Am J Chin Med; 2023; 51(4):1041-1066. PubMed ID: 37120706
[TBL] [Abstract] [Full Text] [Related]
7. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemanuil E; Miyazaki Y; Hellström-Lindberg E; Ogawa S
Blood Adv; 2023 Jul; 7(14):3624-3636. PubMed ID: 36989067
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells.
Zunitch MJ; Fisch AS; Lin B; Barrios-Camacho CM; Faquin WC; Tachie-Baffour Y; Louie JD; Jang W; Curry WT; Gray ST; Lin DT; Schwob JE; Holbrook EH
Mod Pathol; 2023 May; 36(5):100122. PubMed ID: 36841178
[TBL] [Abstract] [Full Text] [Related]
9. LncRNA MALAT1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing VHL through a non-canonical function of ezh2.
Duan Y; Yue K; Ye B; Chen P; Zhang J; He Q; Wu Y; Lai Q; Li H; Wu Y; Jing C; Wang X
Cell Death Dis; 2023 Feb; 14(2):149. PubMed ID: 36813772
[TBL] [Abstract] [Full Text] [Related]
10. ezh2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.
Lin ZS; Chung CC; Liu YC; Chang CH; Liu HC; Liang YY; Huang TL; Chen TM; Lee CH; Tang CH; Hung MC; Chen YH
Elife; 2023 Jan; 12():. PubMed ID: 36622753
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X; Xu T; Lin X; Xu S; Fan Y; Guo B; Deng X; Jiao Q; Chen L; Wei Z; Chen C; Yang W; Zhang Z; Yu X; Yue H
J Clin Endocrinol Metab; 2023 Jun; 108(7):1768-1775. PubMed ID: 36611251
[TBL] [Abstract] [Full Text] [Related]
12. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract] [Full Text] [Related]
13. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
14. CTR9 drives osteochondral lineage differentiation of human mesenchymal stem cells via epigenetic regulation of BMP-2 signaling.
Chan NT; Lee MS; Wang Y; Galipeau J; Li WJ; Xu W
Sci Adv; 2022 Nov; 8(46):eadc9222. PubMed ID: 36383652
[TBL] [Abstract] [Full Text] [Related]
15. BMP2 inhibits cell proliferation by downregulating ezh2 in gastric cancer.
Chen Z; Yuan L; Li X; Yu J; Xu Z
Cell Cycle; 2022 Nov; 21(21):2298-2308. PubMed ID: 35856444
[TBL] [Abstract] [Full Text] [Related]
16. ezh2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.
Wan D; Han X; Zhang C; Zhang Y; Ma Y; Wang G
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1179-1186. PubMed ID: 35818168
[TBL] [Abstract] [Full Text] [Related]
17. SHR2554, an ezh2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
Song Y; Liu Y; Li ZM; Li L; Su H; Jin Z; Zuo X; Wu J; Zhou H; Li K; He C; Zhou J; Qi J; Hao S; Cai Z; Li Y; Wang W; Zhang X; Zou J; Zhu J
Lancet Haematol; 2022 Jul; 9(7):e493-e503. PubMed ID: 35772429
[TBL] [Abstract] [Full Text] [Related]
18. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/ezh2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract] [Full Text] [Related]
19. BET-bromodomain and ezh2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Zaiken MC; Flynn R; Paz KG; Rhee SY; Jin S; Mohamed FA; Saha A; Thangavelu G; Park PMC; Hemming ML; Sage PT; Sharpe AH; DuPage M; Bluestone JA; Panoskaltsis-Mortari A; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Luznik L; Maillard I; Hill GR; MacDonald KPA; Munn DH; Serody JS; Murphy WJ; Kean LS; Zhang Y; Bradner JE; Qi J; Blazar BR
Blood; 2022 May; 139(19):2983-2997. PubMed ID: 35226736
[TBL] [Abstract] [Full Text] [Related]
20. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract] [Full Text] [Related]
[Next]
